Psychogenic Movement Disorders and Other Conversion Disorders

Mark Hallett, MD is Chief of the Human Motor Control Section, Medical Neurology Branch, NINDS, NIH, Bethesda, MD, USA. Anthony E. Lang, MD, FRCPC is Professor and Director of the Division of Neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, and Director of the Movement Disorders Center, Toronto Western Hospital, ON, Canada. Joseph Jankovic, MD is Professor of Neurology, Distinguished Chair in Movement Disorders and Director of the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, Houston, TX, USA. Stanley Fahn, MD is H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders, Columbia University, New York, NY, USA. Peter Halligan PhD, DSc, FBPsS, FPSI, FMedSci is Professor and Dean of Strategic Futures and Interdisciplinary Studies, Department of Psychology, University of Cardiff, UK. Valerie Voon, MD is a Clinical Research Associate in the Behavioral and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, UK. C. Robert Cloninger, MD is Wallace Renard Professor of Psychiatry and Director of the Center for Psychobiology of Personality, Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA.

Preface; Part I. Clinical Issues: 1. Introduction to the psychiatry of conversion disorders; 2. Phenomenology of psychogenic movement disorders; 3. Psychogenic parkinsonism; 4. Epidemiology and clinical impact of psychogenic movement disorders; 5. The Scottish neurological symptoms study: diagnosis and prognosis in 1144 new neurology outpatients with symptoms unexplained by disease; 6. Predisposition and issues of mixed etiology in psychogenic movement disorders; 7. Psychogenic movement disorders in children; 8. Childhood disorders: another perspective; 9. Clinical features and treatment outcome of conversion disorders in children and adolescents; 10. Somatoform disorders and psychogenic movement disorders; 11. Psychogenic non-epileptic seizures; 12. Hypochondriasis and its relationship to somatization; 13. Movement disorders in complex regional pain syndrome – the pain field perspective; 14. Psychogenic dystonia in psychogenic complex regional pain syndrome; 15. Latah and related syndromes; 16. Trauma and dissociation: clinical manifestations epidemiology, pathogenesis and treatment; 17. Psychogenic movement disorders: illness in search of disease?; 18. Possible genetic approaches to conversion; Part II. Physiology: 19. Functional brain imaging of psychogenic paralysis during conversion and hypnosis; 20. Action control in conversion paralysis: evidence from motor imagery; 21. Imaging in psychogenic movement disorders; 22. Imaging: hysterical, hypnotically suggested and malingered limb paralysis; 23. Functional imaging of psychogenic and feigned weakness; 24. An fMRI study of recall of causal life-events in conversion disorder: preliminary evidence of increased orbito-frontal and parietal activation; 25. Cortisol, trauma and threat vigilance in patients with psychogenic non-epileptic seizures; 26. Components of voluntary action; 27. Action selection in psychogenic movement disorders; 28. Insights from physiology: tremor and myoclonus; 29. Physiology of psychogenic dystonia; 30. Evoked potentials in the assessment of patients with suspected psychogenic sensory symptoms; 31. Characterizing and assessing the spectrum of volition in psychogenic movement disorders; Part III. Assessment: 32. Rating scales for psychogenic movement disorders; 33. Quality of life in psychogenic movement disorders: the cause not the effect; 34. Psychiatric testing; 35. Diagnostic considerations for the assessment of malingering within the context of psychogenic movement disorders; Part IV. Treatment: 36. Prognosis in patients with psychogenic movement disorders; 37. Presenting the diagnosis; 38. Patterns of practice [MDS Questionnaire report]; 39. Psychotherapy for psychogenic movement disorders; 40. Pharmacotherapy; 41. Suggestion; 42. Treating psychogenic movement disorders with suggestion; 43. In-patient therapy: trying to transcend pathological dissociation, dependence and disability; 44. Appendix: psychogenic movement disorders, video legends; Index.